Description: Significant consolidation has occurred in the U.S. reinsurance market over the last five years. The number of companies operating in ordinary life reinsurance has continued to decline—13 primary companies excluding retrocessionaires contributing to the Munich American Reassurance Survey in 2004, compared to 20 companies in 1999. Table 1 and Table 2 indicate the change in market share as well as the change in the composition of the leading participants in the U.S. market for 2004 versus 1999.

Description: Cell and Gene Therapy (CGT) are life-changing treatments where conditions such as cancer, hemophilia, spinal muscular atrophy and blindness are being cured. These are great for individuals and society, but the treatment costs are expensive which is bad for payers and reinsurers. This article explores ways for health reinsurance actuaries to participate in the space and evaluate the risk associated with these treatments